Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Series X Non-Voting Convertible PreferredNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Dec 15, 2023 (filed on Dec 18, 2023)Insider Name:Windsor James BrianOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:225Price:$3.37
-
Nov 20, 2023 (filed on Nov 21, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,076Price:$1.97
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Musso Alan AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Fairey WilliamOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Series X Non-Voting Convertible Preferred StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
Filings by filing date
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Series X Non-Voting Convertible PreferredNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2Price:--
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,000Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Ambros Reinhard J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Von Rickenbach Josef HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,725Price:--
-
Dec 15, 2023 (filed on Dec 18, 2023)Insider Name:Windsor James BrianOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:225Price:$3.37
-
Nov 20, 2023 (filed on Nov 21, 2023)Insider Name:Windsor James BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,076Price:$1.97
-
Oct 31, 2023 (filed on Nov 02, 2023)Insider Name:Fairey WilliamOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,450Price:--
-
Oct 31, 2023 (filed on Nov 02, 2023)Insider Name:Musso Alan AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,450Price:--
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Musso Alan AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Nov 02, 2023 (filed on Nov 02, 2023)Insider Name:Fairey WilliamOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 738 Main Street, Unit 398 WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://aileronrx.com |
IR: | See website |
Key People | ||
Brian Windsor President, Chief Executive Officer, Director | Susan L. Drexler Interim Chief Financial Officer |
Business Overview |
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions. |
Financial Overview |
For the nine months ended 30 September 2023, Aileron Therapeutics Inc revenues was not reported. Net loss decreased 63% to $8.4M. Lower net loss reflects Research and development decrease of 88% to $1.8M (expense), General and administrative decrease of 14% to $5.3M (expense), Stock-based Compensation in SGA decrease of 42% to $693K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$5.02 to -$1.85. |
Employees: | 6 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $20.32M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$12.64M as of Sep 30, 2023 |
Net annual income (TTM): | -$12.94M as of Sep 30, 2023 |
Free cash flow (TTM): | -$13.83M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,885,512 as of Jan 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |